Abstract
By virtue of their RNA degrading catalytic activity, ribonucleases are potentially cytotoxic. For the application of these enzymes as therapeutics, however, they have to overcome several obstacles whose interplay is not yet fully understood. Ribonucleases with a basic pI are not only able to interact with the (negatively charged) cellular membrane but they are also distinctively selective for tumor cells. After the (endocytotic) uptake into the cell and release into the cytosol from the endosomes where they have to resist the attack by proteases, they face the cytosolic ribonuclease inhibitor. Only if they are able to evade the tight binding to the inhibitor (or if enough ribonuclease molecules enter the cell to neutralize the inhibitor protein) they are able to attack their target RNA, for which a sufficient ribonucleolytic activity is indispensable. Each of these steps can turn into an insurmountable hurdle spoiling the cytotoxic potential of these enzymes. In the present review I will summarize the status quo of the knowledge on the mechanisms and their interdependence as well as to develop strategies to overcome possible limitations.
Keywords: Ribonuclease, cytotoxicity, internalization, stability, antitumor, therapeutic
Current Pharmaceutical Biotechnology
Title: Aspects of the Cytotoxic Action of Ribonucleases
Volume: 9 Issue: 3
Author(s): Ulrich Arnold
Affiliation:
- Martin-Luther University Halle-Wittenberg, Institute of Biochemistry and Biotechnology, Kurt- Mothes-Str. 3, 06120 Halle, Germany.,Germany
Keywords: Ribonuclease, cytotoxicity, internalization, stability, antitumor, therapeutic
Abstract: By virtue of their RNA degrading catalytic activity, ribonucleases are potentially cytotoxic. For the application of these enzymes as therapeutics, however, they have to overcome several obstacles whose interplay is not yet fully understood. Ribonucleases with a basic pI are not only able to interact with the (negatively charged) cellular membrane but they are also distinctively selective for tumor cells. After the (endocytotic) uptake into the cell and release into the cytosol from the endosomes where they have to resist the attack by proteases, they face the cytosolic ribonuclease inhibitor. Only if they are able to evade the tight binding to the inhibitor (or if enough ribonuclease molecules enter the cell to neutralize the inhibitor protein) they are able to attack their target RNA, for which a sufficient ribonucleolytic activity is indispensable. Each of these steps can turn into an insurmountable hurdle spoiling the cytotoxic potential of these enzymes. In the present review I will summarize the status quo of the knowledge on the mechanisms and their interdependence as well as to develop strategies to overcome possible limitations.
Export Options
About this article
Cite this article as:
Arnold Ulrich, Aspects of the Cytotoxic Action of Ribonucleases, Current Pharmaceutical Biotechnology 2008; 9(3) . https://dx.doi.org/10.2174/138920108784567263
DOI https://dx.doi.org/10.2174/138920108784567263 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Molecular Mechanisms in Aging and Current Strategies to Counteract Sarcopenia
Current Aging Science Types of Voltage-Gated Calcium Channels: Molecular and Electrophysiological Views
Current Hypertension Reviews The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry ADAMs and Ectododomain Proteolytic Shedding in Leucocyte Migration: Focus on L-Selectin and ADAM17
Current Immunology Reviews (Discontinued) PET Measurements of cAMP-Mediated Phosphodiesterase-4 with (R)-[11C]Rolipram
Current Radiopharmaceuticals Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design Triazole Nucleoside Derivatives Bearing Aryl Functionalities on the Nucleobases Show Antiviral and Anticancer Activity
Mini-Reviews in Medicinal Chemistry The Structure and Main Functions of Aminopeptidase N
Current Medicinal Chemistry Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Biodistribution and Tumor Targeting of Indium and Iodine-labeled Shiga Toxin B-Subunit
Current Radiopharmaceuticals MRI Combined with Magnetic Resonance Cholangiopancreatography for Diagnosis of Benign and Malignant Pancreatic Intraductal Papillary Mucinous Neoplasms
Current Medical Imaging Anti-Angiogenic Agents in Pancreatic Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine Xenopus DNA Microarrays
Current Genomics A Fluorescent Alkyllysophospholipid Analog Exhibits Selective Cytotoxicity Against the Hormone-Insensitive Prostate Cancer Cell Line PC3
Anti-Cancer Agents in Medicinal Chemistry Structural Characterization of Recombinant Therapeutic Proteins by Circular Dichroism
Current Pharmaceutical Biotechnology Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Current Drug Targets The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Estrogens and Thyroid Hormones: Non-Genomic Effects are Coupled to Transcription
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)